Overview

SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2023-05-22

Target enrollment:

Participant gender:

Summary

This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients. The main endpoint is to compare the overall survival (OS) of these two regimens above.

Phase:

Phase 3

Details

Lead Sponsor:

Sinocelltech Ltd.

Treatments:

Docetaxel